BT PHARMA is an emerging biopharmaceutical company focused on developing innovative therapeutic vaccines caused by human papillomavirus (HPV) for the treatment of cervical cancer and associated neoplasia. The company's lead candidate therapeutic vaccine, ProCervix® is scheduled to receive approval for Phase I/II clinical trials before the end of 2008. BT PHARMA plans to develop ProCervix® to proof of concept stage.
The company was created in October 2001 and is based in Labège (Toulouse), France.
BT PHARMA enforces its alliance with the Institut Pasteur on the development of therapeutic cancer vaccines.
- 01/14/2008
The Institut Pasteur has agreed to add a new patent under the exclusive license granted to BT PHARMA with regards to the Adenylate Cyclase vector technology.
BT PHARMA appoints Martin Koch as Vice President Finance and Administration
- 09/18/2007
Professional in Biotech Finance brings top management and international experience to BT PHARMA – forerunner in Therapeutic Vaccines
BT Pharma sécurise son essai préclinique avec un "bridge" de 1,3M €
- 06/05/2007
Engagée dans le développement de vaccins thérapeutiques actifs contre le HPV, BT Pharma a opté pour la mise en place des normes GMP très en amont.